Kazuhiro Hasegawa

ORCID

Publication Activity (10 Years)

Years Active: 2024-2024
Publications (10 Years): 13

Top Venues

Clinical and experimental nephrology

International journal of molecular sciences

This page only lists publications with an associated author ORCID identifier.

Publications

Kazuhiro Hasegawa, Masanori Tamaki, Eriko Shibata, Taizo Inagaki, Masanori Minato, Sumiyo Yamaguchi, Ikuko Shimizu, Shinji Miyakami, Miho Tada, Shu Wakino
Ability of NAD and Sirt1 to epigenetically suppress albuminuria. Clinical and experimental nephrology 28 (7) (2024)
Kazuhiro Hasegawa, Masanori Tamaki, Eriko Shibata, Taizo Inagaki, Masanori Minato, Sumiyo Yamaguchi, Ikuko Shimizu, Shinji Miyakami, Miho Tada, Shu Wakino
Ability of NAD and Sirt1 to epigenetically suppress albuminuria. Clinical and experimental nephrology 28 (7) (2024)
Kazuhiro Hasegawa, Masanori Tamaki, Yusuke Sakamaki, Shu Wakino
Nmnat1 Deficiency Causes Mitoribosome Excess in Diabetic Nephropathy Mediated by Transcriptional Repressor HIC1. International journal of molecular sciences 25 (12) (2024)
Kazuhiro Hasegawa, Masanori Tamaki, Eriko Shibata, Taizo Inagaki, Masanori Minato, Sumiyo Yamaguchi, Ikuko Shimizu, Shinji Miyakami, Miho Tada, Shu Wakino
Correction to: Ability of NAD and Sirt1 to epigenetically suppress albuminuria. Clinical and experimental nephrology (2024)
Kazuhiro Hasegawa, Masanori Tamaki, Yusuke Sakamaki, Shu Wakino
Nmnat1 Deficiency Causes Mitoribosome Excess in Diabetic Nephropathy Mediated by Transcriptional Repressor HIC1. International journal of molecular sciences 25 (12) (2024)
Kazuhiro Hasegawa, Masanori Tamaki, Eriko Shibata, Taizo Inagaki, Masanori Minato, Sumiyo Yamaguchi, Ikuko Shimizu, Shinji Miyakami, Miho Tada, Shu Wakino
Ability of NAD and Sirt1 to epigenetically suppress albuminuria. Clinical and experimental nephrology 28 (7) (2024)
Kazuhiro Hasegawa, Masanori Tamaki, Eriko Shibata, Taizo Inagaki, Masanori Minato, Sumiyo Yamaguchi, Ikuko Shimizu, Shinji Miyakami, Miho Tada, Shu Wakino
Ability of NAD and Sirt1 to epigenetically suppress albuminuria. Clinical and experimental nephrology (2024)
Kazuhiro Hasegawa, Masanori Tamaki, Eriko Shibata, Taizo Inagaki, Masanori Minato, Sumiyo Yamaguchi, Ikuko Shimizu, Shinji Miyakami, Miho Tada, Shu Wakino
Ability of NAD and Sirt1 to epigenetically suppress albuminuria. Clinical and experimental nephrology 28 (7) (2024)
Kazuhiro Hasegawa, Masanori Tamaki, Eriko Shibata, Taizo Inagaki, Masanori Minato, Sumiyo Yamaguchi, Ikuko Shimizu, Shinji Miyakami, Miho Tada, Shu Wakino
Ability of NAD and Sirt1 to epigenetically suppress albuminuria. Clinical and experimental nephrology 28 (7) (2024)
Kazuhiro Hasegawa, Masanori Tamaki, Eriko Shibata, Taizo Inagaki, Masanori Minato, Sumiyo Yamaguchi, Ikuko Shimizu, Shinji Miyakami, Miho Tada, Shu Wakino
Ability of NAD and Sirt1 to epigenetically suppress albuminuria. Clinical and experimental nephrology (2024)
Kazuhiro Hasegawa, Masanori Tamaki, Yusuke Sakamaki, Shu Wakino
Nmnat1 Deficiency Causes Mitoribosome Excess in Diabetic Nephropathy Mediated by Transcriptional Repressor HIC1. International journal of molecular sciences 25 (12) (2024)
Kazuhiro Hasegawa, Masanori Tamaki, Eriko Shibata, Taizo Inagaki, Masanori Minato, Sumiyo Yamaguchi, Ikuko Shimizu, Shinji Miyakami, Miho Tada, Shu Wakino
Ability of NAD and Sirt1 to epigenetically suppress albuminuria. Clinical and experimental nephrology 28 (7) (2024)
Kazuhiro Hasegawa, Masanori Tamaki, Eriko Shibata, Taizo Inagaki, Masanori Minato, Sumiyo Yamaguchi, Ikuko Shimizu, Shinji Miyakami, Miho Tada, Shu Wakino
Ability of NAD and Sirt1 to epigenetically suppress albuminuria. Clinical and experimental nephrology (2024)

Kazuhiro Hasegawa.css-eqlu8i{font-size:small;padding-left:4px;}

Publication Activity (10 Years)

Top Topics

Top Venues

Kazuhiro Hasegawa